DGAP-News: Mologen AG

DGAP-News: Mologen AG with poster presentation at ASCO GI 2016

DGAP-News: MOLOGEN AG / Key word(s): Conference MOLOGEN AG with poster presentation at ASCO GI 2016

20.01.2016 / 08:03 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PRESS RELEASE N 2 / 2016 of 01/20/2016

MOLOGEN AG with poster presentation at ASCO GI 2016

Berlin, 20 January 2016 - The biotechnology company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present data on the immunotherapy MGN1703 at the 2016 Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, California (21 - 23 January, 2016). The poster will outline the design of the IMPALA trial including preliminary demographic data as well as stratification factors from the first 200 colorectal cancer patients randomized in the study. IMPALA started in September 2014 and is currently enrolling patients.

Abstract details: Abstract number: TPS785 Title: "Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase 3 IMPALA study" Poster presentation: Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus, 23 January 2016 from 7:00 a.m. to 7:55 a.m. and 12:30 p.m. to 2:00 p.m.

For more information on the 2016 Gastrointestinal Cancers Symposium (ASCO GI) please visit the website: http://gicasym.org/ .

About IMPALA IMPALA (Immunomodulatory MGN1703 in Patients with Advanced Colorectal Carcinoma with tumor reduction during induction treatment) is a randomized, international, multicenter, open-label phase III trial. Based on the findings of the IMPACT study, IMPALA aims to prove that a switch maintenance therapy with an active immunotherapy leads to an increased overall survival of patients who have achieved a response during their first line treatment of metastatic colorectal cancer in combination with or without biologics. The primary endpoint is overall survival and secondary study endpoints include progression-free survival, toxicity and safety, and Quality of Life (QoL).

Approximately 540 patients from more than 100 European centers in eight European countries, including the five major European pharma markets, will participate in the study. IMPALA started to treat the first patients in mid-September 2014. The study is expected to finish enrollment by the end of 2016.

For more information on the trials IMPACT and IMPALA please visit www.clinicaltrials.gov.

MOLOGEN AG With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

The cancer immunotherapy lefitolimod (MGN1703) is the company's lead product and best-in-class TLR9 agonist. Treatment with lefitolimod (MGN1703) triggers a broad and strong activation of the immune system. Due to this mechanism of action, lefitolimod (MGN1703) has the potential to be applied to various indications. Lefitolimod (MGN1703) is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need.

www.mologen.com

Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG.

Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com

Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

---------------------------------------------------------------------------

20.01.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service ---------------------------------------------------------------------------

430861 20.01.2016